Manufacturing and Facilities 2023 eBook
Read the article:
Read the ebook:
Feature|Articles|November 15, 2023
- Manufacturing and Facilities, November 2023 eBook
- Volume 2023 eBook
- Issue 4
- Pages: 22-25
Sustainability Using Zero-Carbon Biopharma Facilities
Author(s)Susan Haigney, Alivia Leon
How can sustainability and zero-carbon initiatives be achieved?
Advertisement
Environmental concerns impact a variety of industries, including bio/pharmaceutical companies. BioPharm International® spoke with
Read this
About the authors
Susan Haigney is managing editor, and Alivia Leon was previously assistant editor, both with BioPharm International®.
Article details
BioPharm International
eBook: Manufacturing and Facilities
November 2023
Pages: 22–25
Citation
When referring to this article, please cite it as Haigney, S. and Leon, A. Sustainability Using Zero-Carbon Biopharma Facilities. BioPharm International’s Manufacturing and Facilities eBook. November 2023.
Articles in this issue
almost 3 years ago
De-Risking Sterile Pharma Manufacture with SUTsalmost 3 years ago
Update on Facilities and Manufacturing Trendsalmost 3 years ago
Tech Transfer and Regulatory Compliancealmost 3 years ago
A Look at Supply Chain for Scale Upalmost 3 years ago
Oligonucleotide Production FacilitiesAdvertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5